CD19

Pages Tagged with "Cd19"

Imugene Licenses CD19 Oncolytic Virus From City of Hope to Turn CAR T Therapy Against Solid Tumors
Imugene Leslie Chong   Managing Director and Chief Executive Officer  +61 458 040 433     City of Hope CONTACT Letisia Marquez 626-476-7593lemarquez@coh.org   Imugene enhances portfolio with novel CD19-expressing...
First chimeric antigen receptor (CAR) T cell therapy targeting B cell-activating factor receptor (BAFF-R) eradicates blood cancers that relapsed after CD19 CAR T therapies
CONTACT Letisia Marquez 626-218-3398lemarquez@coh.org City of Hope’s research on the new CAR T, published in Science Translational Medicine, offers hope for patients who have relapsed after commercially available CD19...
CAR T cell therapy targeting new receptor proves effective for relapsed CAR T patients
Larry Kwak, M.D., Ph.D. The first CAR T cell therapy targeting the B cell-activating factor receptor on cancerous cells eradicated CD19-targeted therapy-resistant human leukemia and lymphoma cells in animal models...
Researchers find that combining two potent immunotherapies can destroy tumors
City of Hope scientists have combined two potent immunotherapies — an oncolytic virus and chimeric antigen receptor (CAR) T cell therapy — to target and eradicate solid tumors that are...
Scientists combine two powerful immunotherapies to eradicate tumors
City of Hope scientists have combined two potent immunotherapies — an oncolytic virus and chimeric antigen receptor (CAR) T cell therapy — to target and eradicate solid tumors that are...